NCT00486135View on ClinicalTrials.gov

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
CancerLymphoma
Interventions
DRUG

XL147 (SAR245408)

Gelatin capsules supplied in 25-mg and 100-mg dosage strengths

DRUG

XL147 (SAR245408)

Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths

Trial Locations (4)

30912

Investigational Site Number 1241, Augusta

75230

Investigational Site Number 1401, Dallas

02115

Investigational Site Number 1503, Boston

08035

Investigational Site Number 3412, Barcelona

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY